Head-To-Head Analysis: Organogenesis (NASDAQ:ORGO) vs. OnKure Therapeutics (NASDAQ:OKUR)

Organogenesis (NASDAQ:ORGO) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation.

Volatility & Risk

Organogenesis has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500. Comparatively, OnKure Therapeutics has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500.

Earnings & Valuation

This table compares Organogenesis and OnKure Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$482.04 million	1.31	$4.95 million	($0.02)	-248.50
OnKure Therapeutics	N/A	N/A	-$77.39 million	($6.57)	-0.73

Organogenesis has higher revenue and earnings than OnKure Therapeutics. Organogenesis is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Organogenesis and OnKure Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	0	1	1	0	2.50
OnKure Therapeutics	0	0	3	2	3.40

Organogenesis currently has a consensus price target of $5.50, suggesting a potential upside of 10.66%. OnKure Therapeutics has a consensus price target of $34.33, suggesting a potential upside of 612.31%. Given OnKure Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe OnKure Therapeutics is more favorable than Organogenesis.

Profitability

This table compares Organogenesis and OnKure Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Organogenesis	-1.62%	-2.69%	-1.63%
OnKure Therapeutics	N/A	-51.17%	-47.11%

Insider and Institutional Ownership

49.6% of Organogenesis shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 36.9% of Organogenesis shares are held by insiders. Comparatively, 17.9% of OnKure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

About Organogenesis

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

About OnKure Therapeutics

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.